What is NDC 0143-9384?

0143-9384 is the product NDC for Fosaprepitant Dimeglumine, Fosaprepitant dimeglumine 150 mg/5mL injection, powder, lyophilized, for solution, listed with the FDA by Hikma Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Hikma Pharmaceuticals USA Inc., NDC labeler code 0143. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Fosaprepitant Dimeglumine?

3 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Fosaprepitant Dimeglumine NDC 0143-9384

NDC codes

FDA NDC Directory

Product NDC (as listed)0143-9384Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00143-9384Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0143-9384-01	0014393840100143938401	1 VIAL, SINGLE-DOSE in 1 CARTON (0143-9384-01) / 5 mL in 1 VIAL, SINGLE-DOSEMarketed from Sep 8, 2020

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fosaprepitant Dimeglumine
Generic name (nonproprietary): fosaprepitant dimeglumine
Active ingredients: Fosaprepitant dimeglumine — 150 mg/5mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Hikma Pharmaceuticals USA Inc.NDC labeler code 0143
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213106
Marketing start: Sep 8, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2C9 Inducers (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Neurokinin 1 Antagonists (Mechanism)
Identifiers: Product ID 0143-9384_ca5262d4-3072-4a53-83e0-435a4d3ca608SPL ID ca5262d4-3072-4a53-83e0-435a4d3ca608SPL set ID 1cc7d482-5d45-4621-9ffc-cd3f7c54614dRxCUI 1731077UNII D35FM8T64X
Pharmacologic class: Substance P/Neurokinin-1 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400143938401 followed by a unit qualifier and the quantity

Package 00143-9384-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 19, 2026.

Indications (excerpt from the label)

Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use Fosaprepitant for Injection has not been studied for the treatment of established nausea and vomiting. Fosaprepitant for Injection is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patien…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0143-9384

What is NDC 0143-9384?: 0143-9384 is the product NDC for Fosaprepitant Dimeglumine, Fosaprepitant dimeglumine 150 mg/5mL injection, powder, lyophilized, for solution, listed with the FDA by Hikma Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Fosaprepitant Dimeglumine.
What is the active ingredient?: Fosaprepitant dimeglumine.
Who is the labeler?: Hikma Pharmaceuticals USA Inc., NDC labeler code 0143. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Fosaprepitant Dimeglumine?: 3 other product NDCs are listed under this name. See all Fosaprepitant Dimeglumine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Fosaprepitant Dimeglumine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Fosaprepitant Dimeglumine	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9428	00143-9428-01
Fosaprepitant Dimeglumine	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Eugia US LLC	55150-299	55150-0299-01
Fosaprepitant Dimeglumine	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Qilu Pharmaceutical Co., Ltd.	67184-0540	67184-0540-01

Other NDCs under ANDA 213106

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213106
Product	Strength	Form · route	Labeler	Product NDC
Fosaprepitant Dimeglumine	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9428
Fosaprepitant Dimeglumine	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Qilu Pharmaceutical Co., Ltd.	67184-0540